|
|
207 Perry Parkway, Suite 2
Gaithersburg, MD 20877 USA
phone:240.243.8000
fax:240.465.0450
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.panaceapharma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Products to treat diseases of the central nervous system and cancer. |
|
| Management |
| Hossein A. Ghanbari, Chairman, CEO & Chief Scientific Officer; Stephen Keith, President and Chief Operating Officer; Steven A. Fuller, Vice President of Product Development; Suzanne M. Sensabaugh, Vice President, Regulatory Affairs; M. Elisa Lane, General Counsel; Michael S. Lebowitz, Director of Research; Zhi-gang Jiang, Director of Neurodegenerative Diseases; Shinji Takeichi, Director of Business Development |
| |
|
|
| |
|
| Keywords |
| oncology, cancer, nervous system, cell cycle abnormalities, neurodegenerative disease, diagnostics, advamed |
|
|
|
| Description |
|
Panacea's mission is to seek, discover, develop, and market innovative products to treat and diagnose diseases of the central nervous system and cancer. |
|
| Products / Services |
PAN-22, a fully human anit-HAAH monoclonal antibody
PAN-622 - Toxin Conjugate
PAN-811
|
|
| Technology / Differentiation |
| Panacea's R & D focus is on novel proteins and biochemical pathways related to cellular regulation and cell cycle abnormalities in oncology and neurodegenerative disease. The Company emphasizes targets with both therapeutic and diagnostic applications, particularly where the diagnostics add significant value to the therapeutic strategies. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
